NovaMedica R&D Center will become a training facility for implementation of modern pharmaceutical technologies
Print 07 February 2018
 |
 |
 |
Moscow, February 7, 2018 – Russian pharmaceutical company NovaMedica (a RMI company) announces start of its cooperation in the area of transfer of knowledge and technologies between the R&D Center of NovaMedica Innotech and the German company Evonik – one of the leading companies in the international market of excipients manufacturing for the pharmaceutical industry. This partnership will result into creation of a training facility for transfer of competences in the area of pharmaceutical technologies at the premises of NovaMedica Innotech in Russia.
Specialists of the R&D Center of NovaMedica will receive from Evonik trainers knowledge and technologies of using excipients which allow to give innovative properties to drug products. For example, such methods and substances are required to ensure sustained duration of a drug product, delayed release of the active component or its targeted delivery into the needed part of the GI tract as well as for manufacturing of prolonged release dosage forms and implants, liposomal and nanosomal injection forms, pharmacopoeial amino acids, ingredients to increase effectiveness of digest medium in the biotech processes, etc. NovaMedica specialists will transfer received knowledge to their colleagues from the Russian pharmaceutical company after they have received the training.
“We are becoming partners in mastering technologies and introducing in Russia innovative excipients which help to manufacture highly-effective drug products of good quality. We are glad that Evonik – one of the major companies in the market – has chosen NovaMedica as its partner which is capable of getting new knowledge and implement cutting-edge international technologies in drug products manufacturing. The most recent developments in the pharmaceutical technologies will be accumulating in our R&D center and we are ready to share new knowledge and experience with our colleagues in the industry”, noted Rustam Iksanov, VP R&D.
About NovaMedica
NovaMedica is a modern Russian pharmaceutical company founded in 2012 by Domain Associates LLC, leading U.S. venture capital firm, and RMI LLC.
NovaMedica's strategy is aimed at search, registration and localization in Russia of intellectual property rights for innovative pharmaceuticals products and technologies, as well as at development and implementation of own R&D projects
NovaMedica became key partner of Pfizer in Russia in 2016. Within this partnership NovaMedica started construction of the pharmaceutical GMP manufacturing facility in the Kaluga region in May 2017. In December 2017 Interdepartmental Commission approved NovaMedica’s application for SPIC to create new pharmaceutical manufacturing facility in the Kaluga region.
In April 2017 NovaMedica opened the Technological Center with state-of-the-art technological capabilities which were previously unavailable in the Russian pharmaceutical industry. In Q4 2017 R&D Center of NovaMedica received manufacturing license and the Russian GMP certificate from the Ministry of Industry and Trade of the Russian Federation.
NovaMedica possesses a well-developed infrastructure for promotion and sale of pharmaceutical products. Currently company is promoting a portfolio of 25 ophthalmological and gastroenterological products in the Russian market.
More information here www.novamedica.com, follow us on Facebook and LinkedIn.
All Portfolio
MEDIA CENTER
-
The RMI group has completed sertain projects
The RMI Group has exited from the capital of portfolio companies:
Marinus Pharmaceuticals, Inc.,
Syndax Pharmaceuticals, Inc.,
Atea Pharmaceuticals, Inc.